Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.47 |
| ▸ | GSK3B | P49841 | 3/20 | 0.47 |
| ▸ | NFATC1 | O95644 | 2/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 6/20 | 0.40 |
| ▸ | CCNK | O75909 | 6/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.40 |
| ▸ | CDK2 | P24941 | 6/20 | 0.40 |
| ▸ | CDK9 | P50750 | 6/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 6/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 7/20 | 0.33 |
| ▸ | CDK7 | P50613 | 3/20 | 0.31 |
| ▸ | CCNH | P51946 | 3/20 | 0.31 |
| ▸ | MNAT1 | P51948 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364406 | 1.00 | DYRK1A (0.47) | DYRK1AGSK3BNFATC1CCNT1CCNK | |
| SCHEMBL29364439 | 0.90 | GSK3B (0.48) | DYRK1AGSK3BNFATC1CCNT1CCNK | |
| SCHEMBL25028661 | 0.90 | GSK3B (0.48) | DYRK1AGSK3BNFATC1CCNT1CCNK | |
| SCHEMBL29361222 | 0.89 | GSK3B (0.45) | DYRK1AGSK3BNFATC1CCNT1CCNK | |
| SCHEMBL25028646 | 0.89 | GSK3B (0.45) | DYRK1AGSK3BNFATC1CCNT1CCNK | |
| SCHEMBL25027562 | 0.89 | GSK3B (0.45) | DYRK1AGSK3BNFATC1CCNT1CCNK | |
| SCHEMBL25274305 | 0.89 | GSK3B (0.45) | DYRK1AGSK3BNFATC1CCNT1CCNK | |
| SCHEMBL26615786 | 0.89 | GSK3B (0.45) | DYRK1AGSK3BNFATC1CCNT1CCNK | |
| SCHEMBL25028895 | 0.86 | DYRK1A (0.45) | DYRK1AGSK3BNFATC1CCNT1CCNK | |
| SCHEMBL25028901 | 0.86 | DYRK1A (0.45) | DYRK1AGSK3BNFATC1CCNT1CCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230049406-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049406-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | DYRK1A 1187/4885GSK3B 463/4885NFATC1 1397/4885 |
| US-20230348439-A1 | INDOLE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | DYRK1A 1097/4885GSK3B 441/4885NFATC1 1359/4885 |
| US-11667624-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | DYRK1A 937/4885GSK3B 468/4885NFATC1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.